Antiviral therapy of decompensated hepatitis B virus-related cirrhosis

Chinese Medical Journal

Volumn 125, Issue 2, 2012, Pages 373-377

  Chen, Guang Cheng ^a   Yu, Tao ^a   Huang, Kai Hong ^a   Chen, Qi Kui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antiviral agents; Decompensated cirrhosis; Hepatitis B virus

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; HEPATITIS B; HEPATORENAL SYNDROME; HUMAN; INFECTION RISK; LIVER DISEASE; LIVER FUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NONHUMAN; PATIENT SELECTION; REBOUND VIREMIA; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT FAILURE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS;

EID: 84862941849     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.02.036     Document Type: Review

References (43)

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 (Suppl 1): 3-8.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. Lok AS. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
4. Liaw YF, Leung N, Kao JH, Priatvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update. Hepatol Int 2008; 2: 263-283.
5. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
6. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006; 26: 142-152.
7. Hui AY, Chan HL, Leung NW, Hung LC, Chan FK, Sung JJ. Survival and prognostic indicators in hepatic B virus-related cirrhosis after onset of hepatitis decompensation. J Clin Gastroenterol 2002; 34: 569-572.
8. Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341.
9. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
10. Zoulim F, Perrillo RP. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl 1): S2-S19.
11. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
12. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
13. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85.
14. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005; 11: 716-732.
15. Lok AS, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B: update 2009. (Accessed June 2, 2010 at www.aasld.org. Accessed.)
16. Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005; 20: 426-432.
17. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann intern Med 2009; 150: 104-110.
18. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597-599.
19. Zhang JM, Wang XY, Huang YX, Yin YK, Guan S, Xu Y, et al. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy. J Med Virol 2006; 78: 324-328.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751.
22. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218.
23. Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6-12.
24. Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, et al. Long-term nucleos analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011; 8: 72.
25. Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 2009; 137: 1680-1686.
26. Wolters LM, Niesters HG, de Man RA. Nucleoside analogues for chronic hepatitis B. Eur J Gastroenterol Hepatol 2001; 13: 1499-1506.
27. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38 Suppl 1: S90-S103.
28. Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2000; 15 Suppl: E53-E60.
29. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210.
30. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-416.
31. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386-392.
32. Mutimer D. Hepatitis B virus infection: resistance to antiviral agents. J Clin Virol 2001; 21: 239-224.
33. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427.
34. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360.
35. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089.
36. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
37. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
38. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggars BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistence to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
39. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182.
40. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
41. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, et al. Tenofovir for patients with lamivudine resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325.
42. Peters MG. Special populations with hepatitis B virus infection. Hepatology 2009; 49 (5 suppl): S146-S155.
43. Chen Y, Cheng G, Mahato RI. RNAi for Treating Hepatitis B Viral Infection. Pharm Res 2008; 25: 72-86.